$TARA
Protara Therapeutics, Inc. Stock $tara

$tara Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000121390024021982 Filed on March 13, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$0.00
YoY Change			-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.103M	$4.660M	$18.49M
YoY Change	-10.59%	-6.86%	-10.37%
% of Gross Profit
Research & Development	$7.748M	$6.381M	$24.99M
YoY Change	50.65%	27.9%	48.67%
% of Gross Profit
Depreciation & Amortization	$83.00K	$107.0K	$341.0K
YoY Change	7.79%	42.67%	37.5%
% of Gross Profit
Operating Expenses	$11.85M	$11.04M	$43.61M
YoY Change	21.77%	10.5%	-34.97%
Operating Profit	-$11.85M		-$43.61M
YoY Change	21.77%		-34.97%
Interest Expense	$756.0K	$820.0K	$3.193M
YoY Change	10.04%	51.29%	187.66%
% of Operating Profit
Other Income/Expense, Net	$756.0K		$3.193M
YoY Change	10.04%		187.66%
Pretax Income	-$11.10M	-$10.22M	-$40.42M
YoY Change	22.66%	-73.77%	-38.71%
Income Tax
% Of Pretax Income
Net Earnings	-$11.10M	-$10.22M	-$40.42M
YoY Change	22.66%	-73.77%	-38.71%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.97		-$3.57
Diluted Earnings Per Share	-$0.97	-$0.90	-$3.57
COMMON SHARES
Basic Shares Outstanding	11.43M shares	11.36M shares	11.33M shares
Diluted Shares Outstanding	11.42M shares		11.33M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$55.22M	$63.08M	$65.58M
YoY Change	-38.3%	-38.31%	-22.27%
Cash & Equivalents	$52.23M	$39.59M	$39.59M
Short-Term Investments	$2.992M	$23.50M	$25.99M
Other Short-Term Assets	$3.000K	$37.00K	$2.883M
YoY Change	-97.64%	-70.87%	123.49%
Inventory
Prepaid Expenses
Receivables		$242.0K	$242.0K
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$57.91M	$68.71M	$68.71M
YoY Change	-38.79%	-20.25%	-20.25%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.213M	$1.296M	$6.560M
YoY Change	-20.25%	-18.59%	-16.63%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$31.00K	$11.00K	$3.689M
YoY Change	-94.71%	-98.29%	165.59%
Total Long-Term Assets	$10.22M	$10.25M	$10.25M
YoY Change	-13.3%	-62.24%	-62.24%
TOTAL ASSETS
Total Short-Term Assets	$57.91M	$68.71M	$68.71M
Total Long-Term Assets	$10.22M	$10.25M	$10.25M
Total Assets	$68.13M	$78.95M	$78.95M
YoY Change	-35.97%	-30.31%	-30.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$972.0K	$2.434M	$2.434M
YoY Change	-76.18%	53.47%	53.47%
Accrued Expenses	$3.529M	$2.732M	$3.715M
YoY Change	152.79%	-15.6%	-10.57%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.501M	$6.149M	$6.149M
YoY Change	-14.18%	7.13%	7.13%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$4.227M	$4.484M	$4.484M
YoY Change	-19.13%	-17.98%	-17.98%
Total Long-Term Liabilities	$4.227M	$4.484M	$4.484M
YoY Change	-19.13%	-17.98%	-17.98%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.501M	$6.149M	$6.149M
Total Long-Term Liabilities	$4.227M	$4.484M	$4.484M
Total Liabilities	$9.728M	$10.63M	$10.63M
YoY Change	-16.4%	-5.12%	-5.12%
SHAREHOLDERS EQUITY
Retained Earnings	-$211.5M	-$200.4M
YoY Change	25.13%	25.27%
Common Stock	$11.00K	$11.00K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$58.41M	$68.32M	$68.32M
YoY Change
Total Liabilities & Shareholders Equity	$68.13M	$78.95M	$78.95M
YoY Change	-35.97%	-30.31%	-30.31%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$11.10M	-$10.22M	-$40.42M
YoY Change	22.66%	-73.77%	-38.71%
Depreciation, Depletion And Amortization	$83.00K	$107.0K	$341.0K
YoY Change	7.79%	42.67%	37.5%
Cash From Operating Activities	-$10.38M	-$8.700M	-$37.56M
YoY Change	-19.47%	73.1%	41.95%
INVESTING ACTIVITIES
Capital Expenditures		-$5.000K	$45.00K
YoY Change		-183.33%	-62.5%
Acquisitions
YoY Change
Other Investing Activities	$23.10M	$14.52M	$53.15M
YoY Change	134.14%	-179.16%	252.7%
Cash From Investing Activities	$23.10M	$14.52M	$53.11M
YoY Change	134.28%	-179.14%	255.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$91.00K
YoY Change			1.11%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$76.00K	-1.000K	-$91.00K
YoY Change	18.75%		1.11%
NET CHANGE
Cash From Operating Activities	-$10.38M	-8.700M	-$37.56M
Cash From Investing Activities	$23.10M	14.52M	$53.11M
Cash From Financing Activities	-$76.00K	-1.000K	-$91.00K
Net Change In Cash	$12.65M	5.818M	$15.46M
YoY Change	-508.96%	-124.89%	-233.3%
FREE CASH FLOW
Cash From Operating Activities	-$10.38M	-$8.700M	-$37.56M
Capital Expenditures		-$5.000K	$45.00K
Free Cash Flow	-$10.38M	-$8.695M	-$37.60M
YoY Change	-19.51%	72.79%	41.48%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11259615	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11331338	shares
CY2022Q4	tara	Corporate Bonds At Carrying Value CorporateBondsAtCarryingValue	2523000	usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-36694
CY2023	dei	Entity Registrant Name EntityRegistrantName	Protara Therapeutics, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-4580525
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	345 Park Avenue South
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	3rd Floor
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10010
CY2023	dei	City Area Code CityAreaCode	(646)
CY2023	dei	Local Phone Number LocalPhoneNumber	844-0337
CY2023	dei	Security12b Title Security12bTitle	common stock, par value $0.001 per share
CY2023	dei	Trading Symbol TradingSymbol	TARA
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	18000000.0	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	11433837	shares
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	New York, New York
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39586000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24127000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	25994000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	60243000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3125000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1776000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	68705000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	86146000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	745000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	745000	usd
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	17886000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1296000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1592000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5264000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6277000	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	2944000	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	644000	usd
CY2023Q4	us-gaap	Assets Assets	78954000	usd
CY2022Q4	us-gaap	Assets Assets	113290000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2434000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1586000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2732000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3237000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	983000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	917000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6149000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5740000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4484000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5467000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	10633000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	11207000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11364903	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11364903	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11267389	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11267389	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	11000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	11000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	268725000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	262724000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-200384000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-159964000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-31000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-688000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	68321000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	102083000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	78954000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	113290000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24989000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16808000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18624000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20737000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	29517000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	43613000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	67062000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-43613000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-67062000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	3193000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	1110000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3193000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1110000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-40420000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-65952000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.57
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.86
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11331338	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11259615	shares
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	657000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-477000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	657000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-477000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-39763000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-66429000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	161914000	usd
CY2022	tara	Settlement Of Restricted Stock Units SettlementOfRestrictedStockUnits	-90000	usd
CY2022	tara	Stock Issued During Period Value Restricted Stock Units StockIssuedDuringPeriodValueRestrictedStockUnits	1273000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5415000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-477000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-65952000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	102083000	usd
CY2023	tara	Settlement Of Restricted Stock Units SettlementOfRestrictedStockUnits	-91000	usd
CY2023	tara	Stock Issued During Period Value Restricted Stock Units StockIssuedDuringPeriodValueRestrictedStockUnits	1208000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4884000	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	657000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-40420000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	68321000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-40420000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-65952000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	29517000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	6092000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	6688000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1013000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1366000	usd
CY2023	us-gaap	Depreciation Depreciation	341000	usd
CY2022	us-gaap	Depreciation Depreciation	248000	usd
CY2023	tara	Amortization Of Discounts And Premiums Investments AmortizationOfDiscountsAndPremiumsInvestments	-444000	usd
CY2022	tara	Amortization Of Discounts And Premiums Investments AmortizationOfDiscountsAndPremiumsInvestments	1137000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1265000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-265000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	2300000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-222000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	848000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	631000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-505000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	748000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-917000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1327000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-37557000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-26457000	usd
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	12186000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	43550000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	65338000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	58620000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	45000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	120000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	53107000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	14950000	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	91000	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	90000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-91000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-90000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	15459000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-11597000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24872000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36469000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40331000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24872000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. Organization and Nature of the Business </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Overview</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Protara Therapeutics, Inc., and its consolidated subsidiaries (“Protara” or the “Company”), is a clinical-stage biopharmaceutical company committed to advancing transformative therapies for the treatment of cancer and rare diseases. Protara’s portfolio includes two development programs utilizing TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer, or NMIBC, and lymphatic malformations, or LMs. The third program in the portfolio is Intravenous, or IV, Choline Chloride, an investigational phospholipid substrate replacement therapy in development for patients receiving parenteral nutrition, or PN.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Liquidity and Capital Resources</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is in the business of developing biopharmaceuticals and has no current or near-term revenues. The Company has incurred substantial clinical and other costs in its drug development efforts. The Company will need to raise additional capital in order to fully realize management’s plans.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes that its current financial resources are sufficient to satisfy the Company’s estimated liquidity needs for at least 12 months from the date of issuance of these consolidated financial statements.</span></p>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of Estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Significant items subject to such estimates include but are not limited to research and development accruals as well as contingencies.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On an ongoing basis, the Company’s management evaluates its estimates based on historical and anticipated results, trends, and various other assumptions believed to be reasonable. Actual results could differ from those estimates. The results of any changes in accounting estimates are reflected in the financial statements of the period in which the change becomes evident.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"> </p>
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39586000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24127000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	745000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	745000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40331000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24872000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentrations of Credit Risk</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments, which potentially subject the Company to concentrations of credit risk, consists principally of cash, cash equivalents, restricted cash, and marketable debt securities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company currently invests its excess cash primarily in money market funds and high quality, investment grade marketable debt securities of corporations. The Company has adopted an investment policy that includes guidelines relative to credit quality, diversification and maturities to preserve principal and liquidity.</span></p>
CY2022	tara	Market Capitalizations Percentage Change MarketCapitalizationsPercentageChange	0.60	pure
CY2022	tara	Microcap Companies Market Capitalization MicrocapCompaniesMarketCapitalization	250000000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	29500000	usd
CY2023	tara	Stock Option Period StockOptionPeriod	P4Y
CY2023	tara	Percentage Of Largest Amount Of Benefit PercentageOfLargestAmountOfBenefit	0.50	pure
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	65770000	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	78129000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	94681000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	26025000	usd
CY2023Q4	tara	Unrealized Losses UnrealizedLosses	-31000	usd
CY2023Q4	tara	Estimated Fair Value EstimatedFairValue	25994000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	78817000	usd
CY2022Q4	tara	Unrealized Losses UnrealizedLosses	-688000	usd
CY2022Q4	tara	Estimated Fair Value EstimatedFairValue	78129000	usd
CY2023	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	usd
CY2022	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	17000	usd
CY2023Q4	tara	Estimated Fair Value EstimatedFairValue	25994000	usd
CY2023Q4	tara	Unrealized Losses UnrealizedLosses	-31000	usd
CY2023	us-gaap	Interest Income Other InterestIncomeOther	2727000	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	2230000	usd
CY2023	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	454000	usd
CY2022	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-1137000	usd
CY2023	us-gaap	Dividend Income Operating DividendIncomeOperating	12000	usd
CY2022	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	17000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	3193000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	1110000	usd
CY2023Q4	tara	Prepaid Research And Development PrepaidResearchAndDevelopment	1957000	usd
CY2022Q4	tara	Prepaid Research And Development PrepaidResearchAndDevelopment	569000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	659000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	288000	usd
CY2023	tara	Accrued Interest On Marketable Debt Securities AccruedInterestOnMarketableDebtSecurities	242000	usd
CY2022	tara	Accrued Interest On Marketable Debt Securities AccruedInterestOnMarketableDebtSecurities	486000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	163000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	184000	usd
CY2023	tara	Prepaid Software PrepaidSoftware	67000	usd
CY2022	tara	Prepaid Software PrepaidSoftware	122000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	37000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	127000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3125000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1776000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2120000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2075000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	824000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	483000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1296000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1592000	usd
CY2023Q4	tara	Prepaid Research And Development Noncurrent PrepaidResearchAndDevelopmentNoncurrent	2661000	usd
CY2022Q4	tara	Prepaid Research And Development Noncurrent PrepaidResearchAndDevelopmentNoncurrent	84000	usd
CY2023Q4	tara	Prepaid Insurance Noncurrent PrepaidInsuranceNoncurrent	272000	usd
CY2022Q4	tara	Prepaid Insurance Noncurrent PrepaidInsuranceNoncurrent	544000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	16000	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	2944000	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	644000	usd
CY2023Q4	tara	Accrued Employee Related Current AccruedEmployeeRelatedCurrent	2112000	usd
CY2022Q4	tara	Accrued Employee Related Current AccruedEmployeeRelatedCurrent	2543000	usd
CY2023Q4	tara	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	440000	usd
CY2022Q4	tara	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	512000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	180000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	182000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2732000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3237000	usd
CY2023Q4	us-gaap	Area Of Land AreaOfLand	10300	sqft
CY2023	us-gaap	Payments For Rent PaymentsForRent	1117000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	745000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	1234000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1327000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	1423000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1366000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	3000	usd
CY2023	us-gaap	Lease Cost LeaseCost	1423000	usd
CY2022	us-gaap	Lease Cost LeaseCost	1369000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.07	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.07	pure
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P55M
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P67M
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1327000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1395000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1429000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1429000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	718000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	87000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	6385000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	918000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	5467000	usd
CY2023	tara	Royalty Expense Lower Range RoyaltyExpenseLowerRange	25000	usd
CY2023	tara	Royalty Expense Upper Range RoyaltyExpenseUpperRange	75000	usd
CY2023	tara	Upper Limit Of Additional Milestone Payments UpperLimitOfAdditionalMilestonePayments	775000	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11364903	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11364903	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11267389	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11267389	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	7.01
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	39087	shares
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-9627000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-7954000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-4124000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1068000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-13751000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	14.23
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y1M28D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.99
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	6.83
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	15.94
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.5
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y10D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	20000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	9.5
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y10D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	20000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	15.48
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y29D
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6092000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6688000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6092000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6688000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-9022000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	13751000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	9022000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	30731000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	26768000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	9611000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	3418000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4464000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2477000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	4824000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3710000	usd
CY2023Q4	tara	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	1485000	usd
CY2022Q4	tara	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	1481000	usd
CY2023Q4	tara	Deferred Tax Assets Restricted Stock Units Expense DeferredTaxAssetsRestrictedStockUnitsExpense	2723000	usd
CY2022Q4	tara	Deferred Tax Assets Restricted Stock Units Expense DeferredTaxAssetsRestrictedStockUnitsExpense	2199000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	467000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	408000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	54305000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	40461000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	52734000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	38983000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1571000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1478000	usd
CY2023Q4	tara	Deferred Tax Liabilities Operating Rightofuse Asset DeferredTaxLiabilitiesOperatingRightofuseAsset	1430000	usd
CY2022Q4	tara	Deferred Tax Liabilities Operating Rightofuse Asset DeferredTaxLiabilitiesOperatingRightofuseAsset	1456000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	-141000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	-22000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1571000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1478000	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023	tara	Effective Income Tax Rate Reconciliation At Federal Income Tax Rate Percent EffectiveIncomeTaxRateReconciliationAtFederalIncomeTaxRatePercent	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.078	pure
CY2023	tara	Apportionments Changes Percentage ApportionmentsChangesPercentage	0.04	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.339	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022	tara	Effective Income Tax Rate Reconciliation At Federal Income Tax Rate Percent EffectiveIncomeTaxRateReconciliationAtFederalIncomeTaxRatePercent	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.022	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.033	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.007	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	0.104	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.17	pure
CY2023	tara	Income Tax Carried Forward Terms IncomeTaxCarriedForwardTerms	P20Y
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	52700000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	39000000	usd
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1	pure
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04	pure
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	237000	usd
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	223000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-40420000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-65952000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11331338	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11259615	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.57
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.86
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11419601	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10343706	shares
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent		usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q4	tara	Unrealized Gains UnrealizedGains		usd
CY2022Q4	tara	Unrealized Gains UnrealizedGains		usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss		usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost		usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023	tara	Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue		usd
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023	tara	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue		usd
CY2023	tara	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue		usd
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11259615	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11331338	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.57
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.86
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001359931

Files In Submission

Name	View Source	Status
0001213900-24-021982-index-headers.html	Edgar Link	pending
0001213900-24-021982-index.html	Edgar Link	pending
0001213900-24-021982.txt	Edgar Link	pending
0001213900-24-021982-xbrl.zip	Edgar Link	pending
f10k2023ex21-1_protarathera.htm	Edgar Link	pending
f10k2023ex23-1_protarathera.htm	Edgar Link	pending
f10k2023ex31-1_protarathera.htm	Edgar Link	pending
f10k2023ex31-2_protarathera.htm	Edgar Link	pending
f10k2023ex32-1_protarathera.htm	Edgar Link	pending
f10k2023ex97-1_protarathera.htm	Edgar Link	pending
f10k2023_protarathera.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
f10k2023_protarathera_htm.xml	Edgar Link	completed
Financial_Report.xlsx	Edgar Link	pending
img_001.jpg	Edgar Link	pending
img_002.jpg	Edgar Link	pending
img_003.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tara-20231231.xsd	Edgar Link	pending
tara-20231231_def.xml	Edgar Link	unprocessable
tara-20231231_lab.xml	Edgar Link	unprocessable
tara-20231231_pre.xml	Edgar Link	unprocessable
tara-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TARA
Protara Therapeutics, Inc. Stock $tara

2024 Q1 Form 10-K Financial Statement

#000121390024021982 Filed on March 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TARA Protara Therapeutics, Inc. Stock $tara

2024 Q1 Form 10-K Financial Statement

#000121390024021982 Filed on March 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TARA
Protara Therapeutics, Inc. Stock $tara